公开(公告)号：US20210093702A1

公开(公告)日：2021-04-01

申请号：US17116845

申请日：2020-12-09

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Claudia WAGNER ,  Julia LEIBOLD ,  Colette SONG

IPC: A61K39/00 ,  A61P35/00 ,  G16B20/20 ,  A61K35/17 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12Q1/6886 ,  G01N33/574

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200338175A1

公开(公告)日：2020-10-29

申请号：US16915323

申请日：2020-06-29

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Jens FRITSCHE ,  Harpreet SINGH ,  Andrea MAHR ,  Martina OTT ,  Claudia WAGNER ,  Oliver SCHOOR

IPC: A61K39/00 ,  C12N15/115 ,  C07K14/47 ,  C07K16/18 ,  C07K14/74

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190388530A1

公开(公告)日：2019-12-26

申请号：US16563096

申请日：2019-09-06

Applicant: Immatics biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Jens FRITSCHE ,  Harpreet SINGH ,  Andrea MAHR ,  Martina OTT ,  Claudia WAGNER ,  Oliver SCHOOR

IPC: A61K39/00 ,  C07K16/18 ,  C07K14/74 ,  C12N15/115 ,  C07K14/47

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190338006A1

公开(公告)日：2019-11-07

申请号：US16520003

申请日：2019-07-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Claudia WAGNER ,  Julia LEIBOLD ,  Colette SONG

IPC: C07K14/47 ,  A61K39/00 ,  C07K14/725 ,  C07K14/74 ,  C12N5/0783 ,  A61K35/17 ,  C07K16/30 ,  C07K16/28 ,  A61P35/00 ,  G16B20/20 ,  G01N33/574 ,  C12Q1/6886

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190135914A1

公开(公告)日：2019-05-09

申请号：US16180980

申请日：2018-11-05

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Felix UNVERDORBEN ,  Sebastian BUNK ,  Martin HOFMANN ,  Dominik MAURER ,  Meike HUTT ,  Claudia WAGNER ,  Leonie ALTEN

IPC: C07K16/28 ,  C12N15/62 ,  C12N5/0783 ,  A61P35/00 ,  C07K14/775

Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

公开(公告)号：US20190002556A1

公开(公告)日：2019-01-03

申请号：US16023731

申请日：2018-06-29

Applicant: Immatics Biotechnologies GmbH

Inventor： Claudia WAGNER ,  Leonie ALTEN ,  Sebastian BUNK ,  Dominik MAURER

IPC: C07K16/26 ,  C12N5/0783 ,  C12N15/85

Abstract: The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular the TAA Serine protease inhibitor Kazal-type 2 (SPINK2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and SPINK2 binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of SPINK2 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

公开(公告)号：US20180207251A1

公开(公告)日：2018-07-26

申请号：US15869471

申请日：2018-01-12

Applicant: immatics biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Jens FRITSCHE ,  Harpreet SINGH ,  Andrea MAHR ,  Martina OTT ,  Claudia WAGNER ,  Oliver SCHOOR

IPC: A61K39/00 ,  C12N15/115 ,  C07K16/18 ,  C07K14/74 ,  C07K14/47

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K39/001174 ,  A61K2039/5158 ,  C07K14/4748 ,  C07K14/70539 ,  C07K16/18 ,  C07K2319/00 ,  C12N15/115 ,  C12N2310/16

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20170165335A1

公开(公告)日：2017-06-15

申请号：US15073528

申请日：2016-03-17

Applicant: immatics biotechnologies GmbH

Inventor： Toni WEINSCHENK ,  Jens FRITSCHE ,  Harpreet SINGH ,  Andrea MAHR ,  Martina OTT ,  Claudia WAGNER ,  Oliver SCHOOR

IPC: A61K39/00 ,  C12N15/115 ,  C07K16/18

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/5158 ,  C07K14/4748 ,  C07K14/70539 ,  C07K16/18 ,  C07K2319/00 ,  C12N15/115 ,  C12N2310/16

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20250019406A1

公开(公告)日：2025-01-16

申请号：US18889991

申请日：2024-09-19

Applicant: Immatics Biotechnologies GmbH ,  Immatics US, Inc.

Inventor： Sebastian BUNK ,  Dominik MAURER ,  Gisela SCHIMMACK ,  Heiko SCHUSTER ,  Claudia WAGNER ,  Sara YOUSEF ,  Amir ALPERT

IPC: C07K14/47 ,  A61K31/437 ,  A61K31/5383 ,  A61K35/17 ,  A61K35/76 ,  C07K14/725 ,  C12N5/0783 ,  G01N15/10 ,  G01N15/14 ,  G01N15/149 ,  G01N33/554

Abstract: The present invention relates to a method for selecting a cell or a virus expressing on its surface an antigen-binding protein specifically binding to a protein antigen of interest (PAI) while counter selection using a similar protein antigen (SPA) is applied. Further, the invention provides a method for determining the sequence of a nucleic acid encoding an antigen-binding protein or an antigen-binding part thereof and a method for producing a cell expressing a nucleic acid encoding an antigen-binding protein or an antigen-binding part thereof. The invention also relates to a method for treating a subject with a selected cell population.

公开(公告)号：US20240228611A1

公开(公告)日：2024-07-11

申请号：US18581837

申请日：2024-02-20

Applicant: Immatics Biotechnologies GmbH

Inventor： Felix UNVERDORBEN ,  Sebastian BUNK ,  Martin HOFMANN ,  Dominik MAURER ,  Meike HUTT ,  Claudia WAGNER ,  Leonie ALTEN

IPC: C07K16/28 ,  A61P35/00 ,  C07K14/725 ,  C07K14/775 ,  C07K14/78 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/62

CPC classification number: C07K16/28 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/775 ,  C07K14/78 ,  C07K16/18 ,  C07K16/2809 ,  C12N5/0636 ,  C12N15/62 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/03 ,  C07K2319/33 ,  C12N2510/00

Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.